Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?
High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany , July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration (HighVolumeHDF) access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to develop a pilot program that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies. Fresenius Medical Care Mexico and CCINSHAE signed a two-year contract to enable the installation of the Fresenius Medical Care 5008S CorDiax technology in participating renal treatment centers in CCINCSHAE Centers in Mexico City (CDMX) and its metropolitan area, for a total of 150 systems in all.
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
![]() FMEA 17 May 2024 | Other | €0.64 Per Share |
![]() FMEA 17 May 2023 | Other | €0.6 Per Share |
![]() FMEA 13 May 2022 | Other | €0.71 Per Share |
![]() FMEA 21 May 2021 | Other | €0.83 Per Share |
![]() FMEA 28 Aug 2020 | Other | €0.72 Per Share |
5 Aug 2025 (In 1 month) Date | | 0.46 Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
5 May 2025 Date | | - Cons. EPS | - EPS |
25 Feb 2025 Date | | - Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
![]() FMEA 17 May 2024 | Other | €0.64 Per Share |
![]() FMEA 17 May 2023 | Other | €0.6 Per Share |
![]() FMEA 13 May 2022 | Other | €0.71 Per Share |
![]() FMEA 21 May 2021 | Other | €0.83 Per Share |
![]() FMEA 28 Aug 2020 | Other | €0.72 Per Share |
5 Aug 2025 (In 1 month) Date | | 0.46 Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
5 May 2025 Date | | - Cons. EPS | - EPS |
25 Feb 2025 Date | | - Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
Medical - Care Facilities Industry | Healthcare Sector | Helen Giza CEO | XSTU Exchange | DE0005785802 ISIN |
DE Country | 112,035 Employees | 23 May 2025 Last Dividend | 4 Dec 2012 Last Split | - IPO Date |
Fresenius Medical Care AG is a leading global provider in the field of dialysis and related services, catered towards individuals suffering from renal diseases. Established in 1996 and headquartered in Bad Homburg, Germany, the company has a broad reach extending across Germany, North America, and other international locations. Fresenius Medical Care AG specializes in delivering dialysis treatment and associated laboratory and diagnostic services mainly through its extensive network of outpatient dialysis clinics. Additionally, the company holds contracts with hospitals in the United States to offer dialysis services to hospitalized end-stage renal disease (ESRD) patients and those facing acute kidney failure. Beyond its core services, Fresenius Medical Care AG is engaged in the development, manufacture, and distribution of a wide range of health care products, as well as in the development and licensing of renal pharmaceuticals. It serves a diverse clientele, including dialysis clinics, hospitals, and specialized treatment facilities, through direct sales and a blend of local sales forces, independent distributors, dealers, and sales agents.
Fresenius Medical Care AG provides a comprehensive suite of products and services tailored to meet the needs of renal disease patients and health care providers: